Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PBMs’ Medicare Formulary Lobbying Takes On New Dimensions

Executive Summary

The Pharmaceutical Care Management Association's efforts to ensure the Medicare model formulary guidelines will enable pharmacy benefit managers to negotiate deep discounts on drugs have expanded to include print advertising and direct appeals to the Centers for Medicare & Medicaid Services

You may also be interested in...



Medicare Rx Coverage Requirements Could Lower Patient Safety, Blues Say

Requiring Medicare drug plans to cover a certain number of drugs could negatively affect patient safety, Excellus BlueCross BlueShield (New York) Chief Pharmacy Officer Joel Owerbach said

Medicare Rx Coverage Requirements Could Lower Patient Safety, Blues Say

Requiring Medicare drug plans to cover a certain number of drugs could negatively affect patient safety, Excellus BlueCross BlueShield (New York) Chief Pharmacy Officer Joel Owerbach said

Rx Industry Supports “Reasonable” Tiered Copays, PhRMA CEO Says

The pharmaceutical industry agrees that "reasonable" tiering of prescription drug copays is an appropriate way to encourage cost-consciousness by consumers, Pharmaceutical Research & Manufacturers of America CEO Alan Holmer told the Pharmaceutical Compliance Congress Nov. 16 in Washington, D.C

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045008

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel